Nonalcoholic fatty liver disease and vascular disease: State-of-the-art

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD), the most common of chronic liver disease in Western Country, is closely related to insulin resistance and oxidative stress and includes a wide spectrum of liver diseases ranging from steatosis alone, usually a benign and non-progressive condition, to nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. NAFLD is considered the hepatic manifestation of the metabolic syndrome with which shares several characteristics, however recent data suggest that NAFLD is linked to increased cardiovascular risk independently of the broad spectrum of risk factors of metabolic syndrome. Accumulating evidence suggests that the clinical burden of NAFLD is not restricted to liver-related morbidity and mortality, with the majority of deaths in NAFLD patients related to cardiovascular disease and cancer and not to the progression of liver disease. Retrospective and prospective studies provide evidence of a strong association between NAFLD and subclinical manifestation of atherosclerosis (increased intima-media thickness, endothelial dysfunction, arterial stiffness, impaired left ventricular function and coronary calcification). A general agreement emerging from these studies indicates that patients with NASH are at higher risk of cardiovascular diseases than those with simple steatosis, emphasizing the role of chronic inflammation in the pathogenesis of atherosclerosis of these patients. It is very likely that the different mechanisms involved in the pathogenesis of atherosclerosis in patients with NAFLD have a different relevance in the patients according to individual genetic background. In conclusion, in the presence of NAFLD patients should undergo a complete cardiovascular evaluation to prevent future atherosclerotic complications. Specific lifestyle modification and aggressive pharmaceutical modification will not only reduce the progression of liver disease, but also reduce morbidity for cardiovascular disease improving overall prognosis and survival.

Original languageEnglish
Pages (from-to)13306-13324
Number of pages19
JournalWorld Journal of Gastroenterology
Volume20
Issue number37
DOIs
Publication statusPublished - Oct 7 2014

Fingerprint

Vascular Diseases
Liver Diseases
Atherosclerosis
Cardiovascular Diseases
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease
Morbidity
Vascular Stiffness
Liver
Left Ventricular Function
Insulin Resistance
Life Style
Oxidative Stress
Chronic Disease
Retrospective Studies
Prospective Studies
Inflammation
Survival
Mortality

Keywords

  • Cardiovascular risk
  • Early atherosclerosis
  • Epicardic fat
  • Inflammation
  • Intima-media thickness
  • Non-alcoholic steatohepatitis
  • Nonalcoholic fatty liver disease
  • Steatosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Nonalcoholic fatty liver disease and vascular disease : State-of-the-art. / Fargion, Silvia; Porzio, Marianna; Fracanzani, Anna Ludovica.

In: World Journal of Gastroenterology, Vol. 20, No. 37, 07.10.2014, p. 13306-13324.

Research output: Contribution to journalArticle

@article{a69e1c4ed3f64098ab51c926d45376b7,
title = "Nonalcoholic fatty liver disease and vascular disease: State-of-the-art",
abstract = "Nonalcoholic fatty liver disease (NAFLD), the most common of chronic liver disease in Western Country, is closely related to insulin resistance and oxidative stress and includes a wide spectrum of liver diseases ranging from steatosis alone, usually a benign and non-progressive condition, to nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. NAFLD is considered the hepatic manifestation of the metabolic syndrome with which shares several characteristics, however recent data suggest that NAFLD is linked to increased cardiovascular risk independently of the broad spectrum of risk factors of metabolic syndrome. Accumulating evidence suggests that the clinical burden of NAFLD is not restricted to liver-related morbidity and mortality, with the majority of deaths in NAFLD patients related to cardiovascular disease and cancer and not to the progression of liver disease. Retrospective and prospective studies provide evidence of a strong association between NAFLD and subclinical manifestation of atherosclerosis (increased intima-media thickness, endothelial dysfunction, arterial stiffness, impaired left ventricular function and coronary calcification). A general agreement emerging from these studies indicates that patients with NASH are at higher risk of cardiovascular diseases than those with simple steatosis, emphasizing the role of chronic inflammation in the pathogenesis of atherosclerosis of these patients. It is very likely that the different mechanisms involved in the pathogenesis of atherosclerosis in patients with NAFLD have a different relevance in the patients according to individual genetic background. In conclusion, in the presence of NAFLD patients should undergo a complete cardiovascular evaluation to prevent future atherosclerotic complications. Specific lifestyle modification and aggressive pharmaceutical modification will not only reduce the progression of liver disease, but also reduce morbidity for cardiovascular disease improving overall prognosis and survival.",
keywords = "Cardiovascular risk, Early atherosclerosis, Epicardic fat, Inflammation, Intima-media thickness, Non-alcoholic steatohepatitis, Nonalcoholic fatty liver disease, Steatosis",
author = "Silvia Fargion and Marianna Porzio and Fracanzani, {Anna Ludovica}",
year = "2014",
month = "10",
day = "7",
doi = "10.3748/wjg.v20.i37.13306",
language = "English",
volume = "20",
pages = "13306--13324",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "37",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease and vascular disease

T2 - State-of-the-art

AU - Fargion, Silvia

AU - Porzio, Marianna

AU - Fracanzani, Anna Ludovica

PY - 2014/10/7

Y1 - 2014/10/7

N2 - Nonalcoholic fatty liver disease (NAFLD), the most common of chronic liver disease in Western Country, is closely related to insulin resistance and oxidative stress and includes a wide spectrum of liver diseases ranging from steatosis alone, usually a benign and non-progressive condition, to nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. NAFLD is considered the hepatic manifestation of the metabolic syndrome with which shares several characteristics, however recent data suggest that NAFLD is linked to increased cardiovascular risk independently of the broad spectrum of risk factors of metabolic syndrome. Accumulating evidence suggests that the clinical burden of NAFLD is not restricted to liver-related morbidity and mortality, with the majority of deaths in NAFLD patients related to cardiovascular disease and cancer and not to the progression of liver disease. Retrospective and prospective studies provide evidence of a strong association between NAFLD and subclinical manifestation of atherosclerosis (increased intima-media thickness, endothelial dysfunction, arterial stiffness, impaired left ventricular function and coronary calcification). A general agreement emerging from these studies indicates that patients with NASH are at higher risk of cardiovascular diseases than those with simple steatosis, emphasizing the role of chronic inflammation in the pathogenesis of atherosclerosis of these patients. It is very likely that the different mechanisms involved in the pathogenesis of atherosclerosis in patients with NAFLD have a different relevance in the patients according to individual genetic background. In conclusion, in the presence of NAFLD patients should undergo a complete cardiovascular evaluation to prevent future atherosclerotic complications. Specific lifestyle modification and aggressive pharmaceutical modification will not only reduce the progression of liver disease, but also reduce morbidity for cardiovascular disease improving overall prognosis and survival.

AB - Nonalcoholic fatty liver disease (NAFLD), the most common of chronic liver disease in Western Country, is closely related to insulin resistance and oxidative stress and includes a wide spectrum of liver diseases ranging from steatosis alone, usually a benign and non-progressive condition, to nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. NAFLD is considered the hepatic manifestation of the metabolic syndrome with which shares several characteristics, however recent data suggest that NAFLD is linked to increased cardiovascular risk independently of the broad spectrum of risk factors of metabolic syndrome. Accumulating evidence suggests that the clinical burden of NAFLD is not restricted to liver-related morbidity and mortality, with the majority of deaths in NAFLD patients related to cardiovascular disease and cancer and not to the progression of liver disease. Retrospective and prospective studies provide evidence of a strong association between NAFLD and subclinical manifestation of atherosclerosis (increased intima-media thickness, endothelial dysfunction, arterial stiffness, impaired left ventricular function and coronary calcification). A general agreement emerging from these studies indicates that patients with NASH are at higher risk of cardiovascular diseases than those with simple steatosis, emphasizing the role of chronic inflammation in the pathogenesis of atherosclerosis of these patients. It is very likely that the different mechanisms involved in the pathogenesis of atherosclerosis in patients with NAFLD have a different relevance in the patients according to individual genetic background. In conclusion, in the presence of NAFLD patients should undergo a complete cardiovascular evaluation to prevent future atherosclerotic complications. Specific lifestyle modification and aggressive pharmaceutical modification will not only reduce the progression of liver disease, but also reduce morbidity for cardiovascular disease improving overall prognosis and survival.

KW - Cardiovascular risk

KW - Early atherosclerosis

KW - Epicardic fat

KW - Inflammation

KW - Intima-media thickness

KW - Non-alcoholic steatohepatitis

KW - Nonalcoholic fatty liver disease

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=84909997067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909997067&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i37.13306

DO - 10.3748/wjg.v20.i37.13306

M3 - Article

C2 - 25309067

AN - SCOPUS:84909997067

VL - 20

SP - 13306

EP - 13324

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 37

ER -